The 2019 E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances was given to Jeffery Kelly, PhD, by the American Chemical Society (ACS) at its national meeting in Orlando, Florida. Kelly received recognition “for his understanding of transthyretin aggregation and discovering tafamidis, the first regulatory agency-approved drug to slow the progression of a neurodegenerative disease by inhibiting protein aggregation.” Kelly is a professor in the Department of Chemistry and also the faculty appointee to the Scripps Research Board of Directors.